D. Boral Capital Has Lowered Expectations for Plus Therapeutics (NASDAQ:PSTV) Stock Price

Plus Therapeutics (NASDAQ:PSTV) had its price objective cut by investment analysts at D. Boral Capital from $5.00 to $4.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

PSTV has been the subject of a number of other reports. Zacks Research lowered Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 11th. Ascendiant Capital Markets decreased their price objective on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, November 21st. HC Wainwright restated a “buy” rating and issued a $2.00 price objective on shares of Plus Therapeutics in a research report on Wednesday, November 26th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $6.75.

Plus Therapeutics Price Performance

Shares of PSTV opened at $0.27 on Thursday. The company has a market capitalization of $37.66 million, a P/E ratio of -0.14 and a beta of 0.85. Plus Therapeutics has a one year low of $0.16 and a one year high of $2.31. The business’s 50 day simple moving average is $0.53 and its 200-day simple moving average is $0.54.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The company had revenue of $1.40 million during the quarter, compared to analyst estimates of $1.50 million. On average, sell-side analysts anticipate that Plus Therapeutics will post -2.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Plus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP bought a new stake in shares of Plus Therapeutics in the 3rd quarter valued at $46,000. Scientech Research LLC bought a new stake in shares of Plus Therapeutics during the third quarter worth $100,000. Altium Capital Management LLC acquired a new stake in shares of Plus Therapeutics during the third quarter worth $628,000. Finally, Jane Street Group LLC acquired a new stake in shares of Plus Therapeutics during the second quarter worth $41,000. Institutional investors own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.